Cosmo flash update: Strong Breezula phase 3 results

Friday, December 5, 2025 @ 12:00 am

Cosmo announced compelling phase 3 results for Breezula in male hair loss. Parallel filings in the US and EU expected in H1 2026 with first approvals by mid-2027. Securing the right commercialization partner(s) will be essential to unleash Breezula’s blockbuster sales potential. Breezula is poised to become a key growth driver alongside GI Genius and Winlevi.

Key catalysts

1. CB-03-10 readout phase Ia trial (H2 2025)
2. Breezula filings US & EU (H1 2026)
3. Winlevi EU launch (H1 2026)

Cosmo Flash Update

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Neurimmune expands collaboration with AstraZeneca to treat light chain amyloidosis

Neurimmune today announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease by entering into an exclusive global collaboration and license agreement to develop NI009, a preclinical human monoclonal antibody designed to target and deplete lambda light chain fibrils and deposits from affected tissues and organs in light c
December 4, 2025

Aurealis Therapeutics: Tripling complete wound closure rate in patients with chronic diabetic foot ulcers

Aurealis Therapeutics Announces Positive Blinded Evaluator Efficacy Results of "DIAMEND" Phase-2 Randomized Controlled Trial (NCT06111183 / EU CT 2022-502048-10-00) with AUP-16, a multi-targeting cell & gene therapy for DFUs and other chronic wounds. Results of the study show that AUP-16 Tripling the Complete Wound Closure Rate in Patients with Chronic Diabetic Foot Ulcers with prior wound dur
December 4, 2025

Macrogen Europe: DNA and RNA extraction from blood samples

Macrogen Europe has expanded the capabilities of its Amsterdam laboratory by introducing DNA and RNA extraction from blood samples, available starting January 2, 2026. This new implementation provides a faster and more accessible option for researchers and biotech partners, including the Swiss biotech community.
December 3, 2025

MUVON Therapeutics: Positive Phase 2 results for stress urinary incontinence therapy

MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269) evaluating its novel proprietary muscle precursor cell (MPC)-based tissue-engineered therapy platform in female stress urinary incontinence (SUI). The study met both its primary and secondary endpoints (p<0.0001), demonstrating significant, cl
December 3, 2025

Pharvaris: Positive pivotal study data for treatment of hereditary angioedema attacks

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of Progression™1 (median 17.47 minutes) and complete symptom resolution (median 11.95 hours) Well-tolerated safety profile of deucrictibant confirmed Efficacy and safety outcomes consistent across
December 3, 2025